Missouri Attorney General Challenges Eli Lilly on Drug Pricing
The state issued a cease-and-desist order after a hospital system lost access to federal discount pricing.
Updated on Oct. 26, 2026 in Healthcare
Live Poll
Should drug manufacturers be allowed to require patient data for hospitals to receive price discounts?
Missouri Attorney General Catherine Hanaway issued a cease-and-desist letter to Eli Lilly after the company ended 340B drug pricing for University of Missouri Health Care. The dispute stems from the drug manufacturer demanding sensitive claims data from hospitals to maintain access to federal discount programs.
Why it matters
The attorney general alleges that Eli Lilly is using its market power to impose higher drug prices by cutting off critical discounts for facilities that refuse to share patient data. This conflict highlights a major tension between pharmaceutical manufacturers and hospital systems over the management of the federal 340B drug program.
The conflict centers on the 340B federal drug pricing program, which allows qualifying hospitals to purchase medications at a discount. University of Missouri Health Care has agreed to provide data temporarily to restore this access following the attorney general's intervention.
The players
Catherine Hanaway
She is the Missouri Attorney General who issued the cease-and-desist order to the pharmaceutical company.
Eli Lilly
This is a global pharmaceutical company that manufactures medications and manages drug pricing programs for hospitals.
University of Missouri Health Care
This is a health system that faced a loss of federal 340B drug pricing after refusing to share sensitive claims data.
The details
Eli Lilly requires hospitals to provide claims data in exchange for medication discounts, a practice that led to the cutoff for University of Missouri Health Care in July. In response to the attorney general's actions, affected individuals are now being directed to file complaints through the official state website.
Timeline
Eli Lilly stopped providing 340B pricing to MU Health Care in July 2026.
The Missouri Attorney General announced the cease-and-desist letter on October 26, 2026.
Market Landscape
This dispute marks a significant intervention in the administration of the federal 340B Drug Pricing Program. By challenging the data requirements imposed by the manufacturer, the state is actively positioning itself against industry practices that limit hospital access to affordable medication.
Patients served by the University of Missouri Health Care system may see continued access to drugs now that pricing has been temporarily restored. The attorney general has also opened a channel for the public to submit formal complaints if they believe they are affected by these pricing practices.
The takeaway
This case underscores the growing friction between pharmaceutical companies and hospital networks over how patient data is handled during contract negotiations. Readers concerned about healthcare costs should monitor how state attorneys general continue to exert pressure on drug pricing transparency requirements.
Further reading
For additional context on the local healthcare sector, visit the St. Louis Healthcare section.
Source note: This article includes information reported by Firstalert4.
Live Poll
Should drug manufacturers be allowed to require patient data for hospitals to receive price discounts?
